Hopital Henri Mondor - 1 rue Gustave Eiffel — Clinical Trial Site

9 Registered trials

4 Currently recruiting

Organisation

Hopital Henri Mondor - 1 rue Gustave Eiffel

Location

Créteil, France

Identifier

ORL-000004298

Address

Av du Mal de Lattre de Tassigny, 94000, France

Departments

cardiology
Hématologie Clinique
Hématologie Clinique et Thérapie Cellulaire
Hematology
Hémopathies Lymphoïdes
Nephrology
oncology
Unité Hémopathies Lymphoïdes & INSERMU955

Clinical trials at this site (9)

Search interface

Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplas… Pending

2024-515362-13-00 Philadelphia-negative myeloproliferative neoplasms are 10
Open label phase II study evaluating the efficacy and safety of the combination of tagraxofusp and venetoclax in treatment-naive blastic pla… Recruiting

2024-511003-42-00 BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS 4 2025-12-11
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant Recruiting

2024-513547-82-00 Transthyretin Amyloidosis 5 2025-03-11
C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting

2023-507871-23-00 Relapsed/Refractory Multiple Myeloma 5 2024-05-27
First-in-human study of OT-A201 in patients with selected hematological malignancies and solid tumors Recruiting

2024-511936-28-00 Relapsed/refractory hematological malignancies or adva 1 2023-05-12
An Interventional and Translational Study investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With M… Ended

2024-510837-16-00 locally-advanced and unresectable or metastatic NSCLC w 4 2022-12-13
Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction tr… Ended

2024-515331-30-00 Primary Central Nervous System Lymphoma (PCNSL) 7 2020-10-30
OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN A… Ended

2024-516048-24-00 CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR I 4 2019-06-19
Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, … Ended

2024-512470-10-00 End-stage Renal disease 11 2018-02-02